CEBPA Mutations in Acute Myeloid Leukemia: Implications in Risk Stratification and Treatment

Overview

Journal Int J Hematol

Specialty Hematology

Date 2024 Apr 26

PMID 38671183

Authors

Feng-Ming Tien

Hsin-An Hou

Affiliations

Soon will be listed here.

Abstract

Mutations in CCAAT enhancer binding protein α (CEBPA) occur in approximately 10% of patients with de novo acute myeloid leukemia (AML). Emerging evidence supports that in-frame mutations in the basic leucine zipper domain of CEBPA (CEBPA) confer a survival benefit, and CEBPA replaced CEBPA double mutations (CEBPA) as a unique entity in the 2022 World Health Organization (WHO-2022) classification and International Consensus Classification (ICC). However, challenges remain in daily clinical practice since more than 30% patients with CEBPA die of AML despite intensive treatment. This review aims to provide a comprehensive summary of the heterogeneities observed in AML with CEBPA and CEBPA, and will discuss the prognostic implications of concurrent mutations and novel mechanistic targets that may inform future drug development. The ultimate goal is to optimize clinical management and to provide precision medicine for this category of patients.

Citing Articles

The Role of Epithelial-to-Mesenchymal Transition Transcription Factors (EMT-TFs) in Acute Myeloid Leukemia Progression.

Cuevas D, Amigo R, Agurto A, Heredia A, Guzman C, Recabal-Beyer A Biomedicines. 2024; 12(8).

PMID: 39200378 PMC: 11351244. DOI: 10.3390/biomedicines12081915.

References

Friedman A, McKnight S . Identification of two polypeptide segments of CCAAT/enhancer-binding protein required for transcriptional activation of the serum albumin gene. Genes Dev. 1990; 4(8):1416-26. DOI: 10.1101/gad.4.8.1416. View

Oelgeschlager M, Nuchprayoon I, Luscher B, Friedman A . C/EBP, c-Myb, and PU.1 cooperate to regulate the neutrophil elastase promoter. Mol Cell Biol. 1996; 16(9):4717-25. PMC: 231472. DOI: 10.1128/MCB.16.9.4717. View

Smith L, Hohaus S, Gonzalez D, Dziennis S, Tenen D . PU.1 (Spi-1) and C/EBP alpha regulate the granulocyte colony-stimulating factor receptor promoter in myeloid cells. Blood. 1996; 88(4):1234-47. View

Cammenga J, Mulloy J, Berguido F, MacGrogan D, Viale A, Nimer S . Induction of C/EBPalpha activity alters gene expression and differentiation of human CD34+ cells. Blood. 2002; 101(6):2206-14. DOI: 10.1182/blood-2002-05-1546. View

Preudhomme C, Sagot C, Boissel N, Cayuela J, Tigaud I, de Botton S . Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA). Blood. 2002; 100(8):2717-23. DOI: 10.1182/blood-2002-03-0990. View

Lin L, Chen C, Lin D, Tsay W, Tang J, Yeh Y . Characterization of CEBPA mutations in acute myeloid leukemia: most patients with CEBPA mutations have biallelic mutations and show a distinct immunophenotype of the leukemic cells. Clin Cancer Res. 2005; 11(4):1372-9. DOI: 10.1158/1078-0432.CCR-04-1816. View

Frohling S, Schlenk R, Stolze I, Bihlmayr J, Benner A, Kreitmeier S . CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations. J Clin Oncol. 2004; 22(4):624-33. DOI: 10.1200/JCO.2004.06.060. View

Taube F, Georgi J, Kramer M, Stasik S, Middeke J, Rollig C . CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome. Blood. 2021; 139(1):87-103. DOI: 10.1182/blood.2020009680. View

Su L, Tan Y, Lin H, Liu X, Yu L, Yang Y . Mutational spectrum of acute myeloid leukemia patients with double mutations based on next-generation sequencing and its prognostic significance. Oncotarget. 2018; 9(38):24970-24979. PMC: 5982761. DOI: 10.18632/oncotarget.23873. View

10.

Konstandin N, Pastore F, Herold T, Dufour A, Rothenberg-Thurley M, Hinrichsen T . Genetic heterogeneity of cytogenetically normal AML with mutations of . Blood Adv. 2018; 2(20):2724-2731. PMC: 6199648. DOI: 10.1182/bloodadvances.2018016840. View

11.

Tien F, Hou H, Tang J, Kuo Y, Chen C, Tsai C . Concomitant mutations predict poor prognosis in acute myeloid leukemia patients with double mutant . Haematologica. 2018; 103(11):e510-e513. PMC: 6278974. DOI: 10.3324/haematol.2018.189043. View

12.

Bienz M, Ludwig M, Oppliger Leibundgut E, Mueller B, Ratschiller D, Solenthaler M . Risk assessment in patients with acute myeloid leukemia and a normal karyotype. Clin Cancer Res. 2005; 11(4):1416-24. DOI: 10.1158/1078-0432.CCR-04-1552. View

13.

Pabst T, Eyholzer M, Fos J, Mueller B . Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favourable prognosis. Br J Cancer. 2009; 100(8):1343-6. PMC: 2676545. DOI: 10.1038/sj.bjc.6604977. View

14.

Dufour A, Schneider F, Metzeler K, Hoster E, Schneider S, Zellmeier E . Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome. J Clin Oncol. 2009; 28(4):570-7. DOI: 10.1200/JCO.2008.21.6010. View

15.

Wouters B, Lowenberg B, Erpelinck-Verschueren C, van Putten W, Valk P, Delwel R . Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome. Blood. 2009; 113(13):3088-91. PMC: 2662648. DOI: 10.1182/blood-2008-09-179895. View

16.

Hou H, Lin L, Chen C, Tien H . Reply to 'Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favorable prognosis'. Br J Cancer. 2009; 101(4):738-40. PMC: 2736811. DOI: 10.1038/sj.bjc.6605207. View

17.

Taskesen E, Bullinger L, Corbacioglu A, Sanders M, Erpelinck C, Wouters B . Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity. Blood. 2010; 117(8):2469-75. DOI: 10.1182/blood-2010-09-307280. View

18.

Arber D, Orazi A, Hasserjian R, Thiele J, Borowitz M, Le Beau M . The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016; 127(20):2391-405. DOI: 10.1182/blood-2016-03-643544. View

19.

Tarlock K, Lamble A, Wang Y, Gerbing R, Ries R, Loken M . CEBPA-bZip mutations are associated with favorable prognosis in de novo AML: a report from the Children's Oncology Group. Blood. 2021; 138(13):1137-1147. PMC: 8570058. DOI: 10.1182/blood.2020009652. View

20.

Khoury J, Solary E, Abla O, Akkari Y, Alaggio R, Apperley J . The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia. 2022; 36(7):1703-1719. PMC: 9252913. DOI: 10.1038/s41375-022-01613-1. View